Leem Jungtae, Lee Seung Min Kathy, Park Jun Hyeong, Lee Suji, Chung Hyemoon, Lee Jung Myung, Kim Weon, Lee Sanghoon, Woo Jong Shin
DongShin Korean Medicine Hospital, 351, Omok-ro, Yangcheon-gu, Seoul, 07999, Republic of Korea.
ChungYeon Medical Institute, 64, Sangmujungang-ro, Seo-gu, Gwangju, 61949, Republic of Korea.
BMC Complement Altern Med. 2017 Jul 11;17(1):361. doi: 10.1186/s12906-017-1864-3.
The purpose of this trial is to evaluate the effectiveness and safety of electroacupuncture in the treatment of acute decompensated heart failure compared with sham electroacupuncture.
This protocol is for a randomized, sham controlled, patient- and assessor-blinded, parallel group, single center clinical trial that can overcome the limitations of previous trials examining acupuncture and heart failure. Forty-four acute decompensated heart failure patients admitted to the cardiology ward will be randomly assigned into the electroacupuncture treatment group (n = 22) or the sham electroacupuncture control group (n = 22). Participants will receive electroacupuncture treatment for 5 days of their hospital stay. The primary outcome of this study is the difference in total diuretic dose between the two groups during hospitalization. On the day of discharge, follow-up heart rate variability, routine blood tests, cardiac biomarkers, high-sensitivity C-reactive protein (hs-CRP) level, and N-terminal pro b-type natriuretic peptide (NT-pro BNP) level will be assessed. Four weeks after discharge, hs-CRP, NT-pro BNP, heart failure symptoms, quality of life, and a pattern identification questionnaire will be used for follow-up analysis. Six months after discharge, major cardiac adverse events and cardiac function measured by echocardiography will be assessed. Adverse events will be recorded during every visit.
The result of this clinical trial will offer evidence of the effectiveness and safety of electroacupuncture for acute decompensated heart failure.
Clinical Research Information Service: KCT0002249 .
本试验旨在评估与假电针相比,电针治疗急性失代偿性心力衰竭的有效性和安全性。
本方案为一项随机、假对照、患者和评估者双盲、平行组、单中心临床试验,可克服以往针刺与心力衰竭试验的局限性。44名入住心内科病房的急性失代偿性心力衰竭患者将被随机分为电针治疗组(n = 22)或假电针对照组(n = 22)。参与者将在住院期间接受5天的电针治疗。本研究的主要结局是两组住院期间总利尿剂剂量的差异。出院当天,将评估随访心率变异性、血常规、心脏生物标志物、高敏C反应蛋白(hs-CRP)水平和N末端B型利钠肽原(NT-pro BNP)水平。出院后四周,将使用hs-CRP、NT-pro BNP、心力衰竭症状、生活质量和辨证问卷进行随访分析。出院后六个月,将评估主要心脏不良事件和通过超声心动图测量的心脏功能。每次就诊时记录不良事件。
本临床试验结果将为电针治疗急性失代偿性心力衰竭的有效性和安全性提供证据。
临床研究信息服务:KCT0002249 。